Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tozorakimab in Diabetic Kidney Disease
NCT04170543Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2019
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of tozorakimab in diabetic kidney disease (DKD) (5 arms), sponsored by AstraZeneca. Primary endpoint: Percent Change From Baseline to Day 169 in Urine Albumin-Creatinine Ratio. Started Nov 2019; status: completed.
02
Drugs
tozorakimab
03
Conditions
diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT04170543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04170543.